Claims for Patent: 8,945,573

Summary for Patent: 8,945,573

Title:	Targeted identification of immunogenic peptides
Abstract:	This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.
Inventor(s):	Ponniah; Sathibalan (Columbia, MD), Peoples; George E. (Fulton, MD), Storrer; Catherine E. (Columbia, MD), Flora; Michael (Mt. Airy, MD)
Assignee:	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (Rockville, MD)
Application Number:	12/045,402
Patent Claims:	1. A method for treating a patient having tumor cells that express a Her2/neu antigen, the method comprising, administering to the patient in any order an immunotherapy consisting of: (a) a therapeutically effective amount of trastuzumab; and (b) a therapeutically effective amount of a peptide vaccine comprising a Her2/neu peptide antigen that consists of the amino acid sequence of SEQ ID NO: 17 (GP2=IISAVVGIL) or SEQ ID NO: 18 (GP2'=IVSAVVGIL), as the sole peptide antigen in the vaccine. 2. The method of claim 1, wherein the Her2/neu peptide antigen is administered before, after or at the same time as administration of the trastuzumab. 3. The method of claim 1, wherein the patient is a breast cancer patient. 4. The method of claim 1, wherein the Her2/neu peptide antigen consists of the amino acid sequence of SEQ ID NO: 17. 5. The method of claim 1, wherein the Her2/neu peptide antigen consists of the amino acid sequence of SEQ ID NO: 18. 6. The method of claim 1, wherein the Her2/neu peptide antigen is administered after the trastuzumab. 7. The method of claim 4, wherein the patient is a breast cancer patient. 8. The method of claim 5, wherein the patient is a breast cancer patient. 9. The method of claim 7, wherein the Her2/neu peptide antigen is administered after the trastuzumab. 10. The method of claim 8, wherein the Her2/neu peptide antigen is administered after the trastuzumab.

Details for Patent 8,945,573

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2025-09-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2025-09-08
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2025-09-08